Background & Aims The prevalence of non-alcoholic fatty liver disease (NAFLD) is
increasing. We aimed to estimate the pooled global NAFLD incidence. Methods We …

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup
metabolic dysfunction-associated steatohepatitis (MASH) have become a global epidemic …

Nonalcoholic fatty liver disease (NAFLD) has become a common health care burden
worldwide. The high heterogeneity of NAFLD remains elusive and impairs outcomes of …

In vitro models of liver (patho) physiology, new technologies, and experimental approaches
are progressing rapidly. Based on cell lines, induced pluripotent stem cells or primary cells …

Semaglutide, a glucagon-like peptide-1 receptor agonist, is an antidiabetic medication that
has recently been approved for the treatment of obesity as well. Semaglutide is postulated to …

Nonalcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease
worldwide and a leading indication for liver transplantation in the United States. NAFLD …

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging
from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis may result …

Background and aim Clinical evidence for early identification and diagnosis of liver cirrhosis
(LC) caused by different types of liver disease is limited. We investigated this topic through a …

NAFLD and its inflammatory condition NASH, which is more likely to progress to fibrosis and
advanced liver disease, are the histologic manifestation of a heterogeneous disease closely …

The incidence of MASLD and MASH-associated fibrosis is rapidly increasing worldwide.
Drug therapy is hampered by large patient variability and partial representation of human …